Medications

FDA approves first liquid, nonstimulant ADHD treatment

The U.S. Food and Drug Administration has approved Tris Pharma's once-daily Onyda XR (clonidine hydrochloride) as the first liquid, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD).

Oncology & Cancer

Team finds new potential causes of rare and lethal bone cancer

Little is known about the genetics and biology of chordoma, a rare and aggressive bone tumor. Chordomas occur in approximately one in a million people in the U.S. a year and 5% of these are in children. These tumors can arise ...

Health

New sweat monitoring device doesn't require physical activity

Sweat contains biomarkers that can monitor various health conditions, from diabetes to genetic disorders. Sweat sampling, unlike blood collection, is preferred by users due to its painless nature. However, to obtain sufficient ...

page 2 from 40